BRA
TRIL

Blue Rock Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Blue Rock Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-60,094
Closed -$854K – 107
2020
Q3 		$854K Buy
+60,094
New +$599K 0.74% 53

Other funds holding TRIL

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Blue Rock Advisors's TRIL Position: Q4 2020 in Review

Blue Rock Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2020, closing a stake of 60,094 shares — an estimated $854K sold.

Blue Rock Advisors first reported a position in TRIL in Q3 2020 and held it in 1 quarter. The position peaked at $854K in Q3 2020. 131 funds tracked by Wall St. Rank hold TRIL as of Q4 2020.

  • Blue Rock Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2020 after selling out during the quarter.
  • Blue Rock Advisors sold 60,094 Trillium Therapeutics Inc. shares in Q4 2020, an estimated $854K.
  • Blue Rock Advisors first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 1 quarter.
  • Blue Rock Advisors's Trillium Therapeutics Inc. position peaked at $854K in Q3 2020.
  • 131 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2020.

Based on Blue Rock Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.